Monopar Therapeutics Inc. Deferred Income Tax Expense (Benefit)
Monopar Therapeutics Inc. (MNPR) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-27
- Monopar Therapeutics Inc. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- Monopar Therapeutics Inc. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- Monopar Therapeutics Inc. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- Monopar Therapeutics Inc. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-27 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-27 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-28 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 | |
| 2020-12-31 | $0.00 10-K · filed 2022-03-24 | |
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 | |
| 2018-12-31 | -$71.61K 10-K · filed 2019-02-26 | |
| 2017-12-31 | $0.00 10-K · filed 2019-02-26 | $1.01M 10-K · filed 2018-03-26 |
| 2016-12-31 | $535.25K 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |